Stock Track | ImmunityBio Stock Soars 5.19% on Promising ANKTIVA Bladder Cancer Data

Stock Track11-19 22:42

ImmunityBio, Inc. (IBRX) saw its stock soar 5.19% during Tuesday's pre-market session, following the biotech company's announcement of compelling new clinical data for its ANKTIVA product candidate in treating bladder cancer.

The company reported that in its ongoing QUILT 3.032 study, 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) were treated with ANKTIVA in combination with BCG, achieving an impressive 71% complete response rate. More notably, the duration of response in these responders extended up to an encouraging 54 months.

This positive data update has prompted ImmunityBio to submit a Marketing Authorization Application to the European Medicines Agency (EMA) during the fourth quarter of 2024, seeking regulatory approval to commercialize ANKTIVA in the European Union for this indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155572306?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155572306","market":"us","top_or_hot":-1,"title":"Stock Track | ImmunityBio Stock Soars 5.19% on Promising ANKTIVA Bladder Cancer Data","media":"Stock Track","content":"<p>ImmunityBio, Inc. (IBRX) saw its stock soar 5.19% during Tuesday's pre-market session, following the biotech company's announcement of compelling new clinical data for its ANKTIVA product candidate in treating bladder cancer.</p>\n\n<p>The company reported that in its ongoing QUILT 3.032 study, 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) were treated with ANKTIVA in combination with BCG, achieving an impressive 71% complete response rate. More notably, the duration of response in these responders extended up to an encouraging 54 months.</p>\n\n<p>This positive data update has prompted ImmunityBio to submit a Marketing Authorization Application to the European Medicines Agency (EMA) during the fourth quarter of 2024, seeking regulatory approval to commercialize ANKTIVA in the European Union for this indication.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Stock Soars 5.19% on Promising ANKTIVA Bladder Cancer Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Stock Soars 5.19% on Promising ANKTIVA Bladder Cancer Data\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-19 22:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunityBio, Inc. (IBRX) saw its stock soar 5.19% during Tuesday's pre-market session, following the biotech company's announcement of compelling new clinical data for its ANKTIVA product candidate in...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1155572306","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155572306","pubTimestamp":1732027355,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc.  saw its stock soar 5.19% during Tuesday's pre-market session, following the biotech company's announcement of compelling new clinical data for its ANKTIVA product candidate in treating bladder cancer.The company reported that in its ongoing QUILT 3.032 study, 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ  were treated with ANKTIVA in combination with BCG, achieving an impressive 71% complete response rate. More notably, the durati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"股票追踪ImmunityBio股价因ANKTIVA膀胱癌数据前景乐观而飙升5.19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (IBRX) saw its stock soar 5.19% during Tuesday's pre-market session, following the biotech company's announcement of compelling new clinical data for its ANKTIVA product candidate in treating bladder cancer.\nThe company reported that in its ongoing QUILT 3.032 study, 100 patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) were treated with ANKTIVA in combination with BCG, achieving an impressive 71% complete response rate. More notably, the duration of response in these responders extended up to an encouraging 54 months.\nThis positive data update has prompted ImmunityBio to submit a Marketing Authorization Application to the European Medicines Agency (EMA) during the fourth quarter of 2024, seeking regulatory approval to commercialize ANKTIVA in the European Union for this indication.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155572306"}